|
Sep 3
|
Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference
|
|
Jul 30
|
Cassava Sciences Announces Expansion of Open-Label Extension Trials
|
|
Jul 22
|
Cassava Shares Rise After Incoming Chairman Gives Timeline for Alzheimer's Drug Study Read Out
|
|
Jul 22
|
Why Cassava Sciences Stock Is Skyrocketing Today
|
|
May 10
|
Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam
|
|
May 8
|
Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution
|
|
May 1
|
Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ
|
|
Apr 30
|
Stock Market Crash Warning: Don’t Get Caught Holding These 3 Biotech Stocks
|
|
Apr 15
|
Redemption Date Announced for Warrants
|
|
Mar 25
|
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
|
|
Mar 6
|
Bullish Cassava Sciences Insiders Loaded Up On US$3.12m Of Stock
|
|
Mar 4
|
Cassava Sciences Announces Virtual Presentation at the AD/PD™ 2024 International Conference
|
|
Feb 7
|
No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months
|
|
Jan 16
|
Cassava Sciences Stock Continues Showing Rising Relative Strength
|
|
Jan 5
|
Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders
|
|
Dec 20
|
Companies Like Cassava Sciences (NASDAQ:SAVA) Are In A Position To Invest In Growth
|
|
Dec 9
|
Why Cassava Sciences Stock Soared Today
|
|
Dec 7
|
Cassava Sciences Appoints Three New Members to its Board of Directors
|
|
Oct 16
|
Is This The End Of Naked Short Selling?
|
|
Oct 13
|
Cassava Sciences Adviser Found to Have Committed ‘Egregious Misconduct’
|